Hygeia Business Model Canvas

Collaborations with pharma and biotech grant Hygeia access to novel immuno-oncology and targeted agents, driving portfolio growth as IO/targeted therapies comprised over 40% of oncology approvals in 2023–2024. Joint clinical programs expand treatment options and can improve outcomes, supporting faster enrollment and real-world evidence generation. Integration of companion diagnostics (market >$6 billion in 2024) and value-based arrangements (reducing patient OOP costs and aligning pricing to outcomes) optimizes patient selection and affordability.

Hygeia’s key partnerships span hospitals (steady oncology referrals), OEMs (LINAC/proton; 7–10y cycles; 124 proton centers in 2024), pharma/diagnostics (IO/targeted >40% approvals 2023–24; companion dx market >$6B in 2024), regulators/payers (reimbursement pilots) and NCI/universities (72 NCI centers; >430,000 ClinicalTrials.gov studies 2024) to secure referrals, tech, trials and funding.

Implement evidence-based protocols and rigorous QA for radiation planning and delivery, with peer review prompting plan changes in 10–25% of cases; standardized workflows aim for >90% protocol adherence. Credentialing and regular audits verify clinician proficiency and compliance. Systematic outcomes measurement (local control, toxicity, PROMs) drives continuous improvement. Patient safety programs, including checklists and incident learning, can cut adverse events by ~30%.

Integrated oncology ops: radiotherapy ≈40% of cures (2024), MDT boards alter ~30% of plans, pathways boost outcomes 20–30% and PROMs guide care. Scale via site selection/licensing; IARC 19.3M cases (2020) drives volume and capex for equipment/PMI. Tech: AI contouring ≈50% planning time savings, interoperability prioritized by 78% (HIMSS 2024), breach cost ≈$4.45M. Navigation shortens time-to-treatment 7–14d; tele-oncology ≈20% follow-ups (2024).

Regulatory approvals and inclusion in national and provincial reimbursement lists are critical for Hygeia to access China’s basic medical insurance pool of ~1.36 billion enrollees in 2024, directly increasing eligible patient volumes. DRG/DIP payment pathways set case-based prices and drive utilization patterns, affecting average revenue per admission. Strategic payer relationships with public and commercial insurers stabilize cash flows and shorten reimbursement cycles. Rigorous compliance reduces audit-related shutdowns and financial penalties, mitigating operational risk.

Hygeia’s key resources combine specialist teams, high-end radiotherapy hardware (LINAC $3–5M; HDR $150–300k; CT/MRI/PET‑CT $2–3M), and 10,000+ annotated cases (2024) supporting quality care for 19.3M annual cancer cases (IARC GLOBOCAN 2020). Inclusion in China’s 1.36B basic insurance pool (2024) and 95–98% LINAC uptime targets drive volume and revenue stability.

Benchmark protocols and rigorous QA align with WHO findings that unsafe care drives an estimated 134 million adverse events and 2.6 million deaths annually in low- and middle-income countries, underscoring need for dependable outcomes across sites. Data-driven oversight leverages continuous monitoring to reduce errors and variability; CMS value-based programs tie transparent metrics to reimbursement, reinforcing patient and payer confidence. Continuous improvement cycles sustain measurable quality gains over time.

Integrated radiotherapy, systemic therapy, diagnostics and supportive care reduce fragmentation for portions of the 19.3 million new cancer cases (IARC 2020).

Modern modalities (IMRT/VMAT/SBRT) improve toxicity and control—PARSPORT: grade 2+ xerostomia 74%→39% at 12 months; SBRT local control ~90–95% (early lung).

Distributed clinics + telehealth cut travel up to 60% (2024 analyses); payer inclusion and package pricing lower OOP.

Physician liaison teams maintain active relationships with referring doctors, supporting a 15% referral uplift in 2024 through targeted outreach; accredited CME programs share protocols and outcomes to align care pathways; rapid consult channels with a 24-hour response target foster trust and reduce decision time; continuous feedback loops enhance coordination, lowering referral-to-admit variance and improving follow-up adherence.

Assigned navigators cut missed visits 22% (2024); proactive follow-ups raised adherence 15% and satisfaction 18%. Omnichannel support handled ~70% of routine queries and bilingual services expanded reach. PRO sharing and dashboards drove transparency; PRO adoption ≥60% across OECD (2024).

Mobile app and web portal manage booking, EHR access and tele-consults, streamlining workflows as the global telemedicine market topped about $100 billion in 2024. Remote planning reviews enable second opinions in multidisciplinary care, used in over 40% more oncology cases versus 2019. Educational content increases uptake and awareness, while secure messaging sustains continuity and reduces coordination delays.

On-site co-located units are primary channels, shortening transfers and signaling reliability. 2024 e-referral portal cut admin steps ~35% and brought urgent referral-to-booking to 24–48 hours; 15% daily capacity reserved for rapid slots. Digital tools, tele-consults and payer/employer steerage (employer coverage ~150M US in 2024) expanded access and improved referrer satisfaction ~22% YoY.

Public and commercial payers prioritize cost-effectiveness and measurable outcomes, driving coverage decisions and value-based contracting; CMS projects US national health expenditures near $5.0 trillion in 2024. They require strict compliance and data transparency for audits and quality metrics, favoring standardized bundled payments and predictable utilization patterns. Payers steer patient flow through narrow networks and referral design, influencing volume and revenue for provider partners.

Adult cancer patients/families: 1,958,310 new US cases (2024) seeking diagnosis, multimodal care and coordination. Referring clinicians: prefer rapid access and shared protocols; co-management links to ~15% shorter LOS. Payers: US health spending ~$5.0T (2024), pushing value contracts. Employers: avg family premium $23,424 (2024); research partners: >430,000 trials and >$200B pharma R&D (2024).

Service contracts, parts and radiation supplies typically represent 10–20% of equipment capital per year, underpinning >98% uptime. QA tools and software licenses are recurring expenses, often 3–6% of annual OPEX. Utility costs are energy‑intensive, with imaging suites consuming ~50–150 kWh/day. Tight inventory management can reduce consumable waste 15–25% (2024 data).

High capital: LINACs $2.5–5.0M, imaging $0.5–3M, build-outs $0.5–3M; financing at ~6–9% (2024) compresses cash flow. Clinical payroll >60% OPEX (oncologist ~$400k, physicist ~$150k); turnover 18–22%. Recurring costs: service/parts 10–20% capex/yr, QA/licenses 3–6% OPEX, malpractice $20–120k/physician.

Infusions, oral oncolytics management and supportive care deliver predictable cash flows; in 2024 outpatient oncology represented a growing share of cancer care revenue as oral agents comprise about 25% of prescriptions. Day-care chemo models can raise chair throughput ~30%, pharmacy margins (typically 8–12%) add gross margin, and strict protocol adherence has been shown to cut complication-related ED visits/hospitalizations by up to 40%.

Hygeia revenue mixes radiotherapy ($200–$500/fraction; courses $6k–$20k), diagnostics (imaging market ~$43B, molecular ~$14B in 2024), infusions/oral agents (oral ≈25% of oncology Rx; pharmacy margins 8–12%), trials/grants (NIH FY2024 ≈49.6B) and management/JV fees (management 3–10% of revenue; JV profit-share 20–40%).